1. Introduction {#s0005}
===============

Bipolar disorder (BD) is characterized by episodes of mania, hypomania and depression and the wellbeing state between the episodes called euthymia ([@bb0020]). The lifetime prevalence is 0.6% for BD type I (BDI), 0.4% for BD type II and extends to 2.4% considering the whole spectrum of BD ([@bb0200]).

BD is arguably one of the most heritable of the Axis I disorders with a heritability estimate to be as high as 93% ([@bb0175]). One way to investigate vulnerability factors for highly heritable diseases like BD is an endophenotype based approach ([@bb0140]). An endophenotype is a biomarker, which is heritable, associated with illness, state-independent, co-segregates with illness in families and is found at a higher rate in non-effected family members compared to general population ([@bb0110]). A wide variety of endophenotypes have been proposed in the psychiatric literature and advanced tools of neuroimaging such as structural magnetic resonance imaging (sMRI) promise to expand these further ([@bb0110]).

sMRI in BD has been the focus of attention for \>20 years with the majority of studies in the literature examining gray matter volume. So far, the most consistent findings in BD patients are reduced volume in insula ([@bb0045]; [@bb0065]; [@bb0250]), anterior cingulate cortex (ACC) ([@bb0045]; [@bb0065]), inferior frontal cortex (IFC) ([@bb0150]; [@bb0250]) and enlargement in lateral ventricles ([@bb0025]; [@bb0170]) compared to healthy controls (HC). Gray matter volume changes in the relatives of BD patients are inconclusive but there are few replicated findings which includes increased volume in IFC, amygdala, caudate, parahippocampal cortex and decreased volume in orbitofrontal cortex (OFC), insula and cerebellum compared to HC ([@bb0205]).

Gray matter volume is a function of two different morphometric structures called as cortical thickness (CT) and surface area (SA) ([@bb0125]; [@bb0265]). While SA is reflective of number of columns, CT measures reflect the number of cells within each column ([@bb0125]). CT and SA are both heritable, globally and regionally independent and genetically uncorrelated ([@bb0255]). It has been argued that these indices should be studied separately and may be preferred over gray matter volume in terms of brain imaging endophenotype ([@bb0265]). Recent advances in neuroimaging analysis such as surface based techniques enable researchers to measure these two different cortical indices accurately ([@bb0265]).

To date, studies on CT in BD patients have revealed some consistent results including cortical thinning in ACC, OFC, paracingulate, dorsolateral, ventrolateral, superior frontal and superior temporal cortex (STC) compared to HC ([@bb0125]). In terms of SA in BD; although a number of studies did not find significant results ([@bb0070]; [@bb0095]; [@bb0160]; [@bb0230]; [@bb0235]), other studies reported increased SA in STC, precuneus, insula, temporal pole, supramarginal, postcentral and superior frontal cortex and decreased SA in frontotemporal cortices and posterior cingulate cortex in BD patients compared to HC ([@bb0010]; [@bb0100]; [@bb0135]). In addition to these small sample sized studies on cortical abnormalities in BD, a mega analysis by ENIGMA consortium, which was comprised of 2447 BD patients and 4056 HC, was conducted recently. This largest study to date showed decreased CT in pars opercularis, fusiform and rostral middle frontal cortex in BD patients compared to HC but didn\'t show any differences in SA between groups ([@bb0145]).

Regarding CT and SA in relatives of BD patients, 6 studies have been conducted. Two heritability studies revealed that cortical thickening in supramarginal cortex and rolandic operculum, SA expansion in supramarginal, inferior parietal and posterior cingulate cortex and cortical thinning in STC, IFC, OFC, inferior temporal, fusiform and lingual cortex are associated with genetic liability to develop BD in unaffected relatives ([@bb0035]; [@bb0080]). The rest four studies showed cortical thinning in IFC, STC, parahippocampal, middle and inferior temporal, middle frontal, fusiform and supramarginal cortex, cortical thickening in postcentral cortex ([@bb0130]; [@bb0220]; [@bb0235]) and no differences in CT or SA ([@bb0235]; [@bb0255]) in the relatives of BD compared to HC.

We recently reported gray matter volume results from the same cohort with a significant main effect of the group in cerebellum, IFC, parahippocampal, lingual, posterior cingulate and supramarginal cortex. Larger IFC and smaller cerebellum were demonstrated in both BDI and FR ([@bb0240]). In the present study, we primarily aimed to investigate gray matter volume determinants, CT and SA, between BDI patients, their FR and HC. Based on the studies in the literature and our previous findings, ACC and IFC were considered as strong candidates to be a BDI endophenotype and were selected as regions of interest (ROIs) for this study. We also aimed to conduct an exploratory analysis of SA and CT of other brain regions apart from the defined ROIs between groups to provide information for future research. Considering the summarized literature above, we hypothesized that BD and FR will have decreased CT and/or SA of the defined ROIs and will differ from HC.

2. Methods and materials {#s0010}
========================

2.1. Participants {#s0015}
-----------------

This study was approved by Dokuz Eylul University Hospital Ethics Committee and was conducted between January 2012 and January 2014 in accordance with the latest version of Declaration of Helsinki. All participants provided written informed consent. BDI patients were recruited from Bipolar Disorder Outpatient Unit, Department of Psychiatry, Dokuz Eylul University, where they had been receiving their monthly follow-up care. For the recruitment of the relative group, unaffected FRs of the enrolled patients were first approached for participation. Nevertheless, due to either lack or unavailability of an unaffected FR for each study patient, FRs of non-study patients were also recruited through advertisements at inpatient and outpatient unit. HCs were recruited through advertisements at the university hospital and on medical school campus. The inclusion criteria for patient group were having a diagnosis of BDI according to DSM-IV, aging between 18 and 65 years, being in euthymic state (according to DSM-IV and scoring ≤7 on both Young Mania Rating Scale and Hamilton Rating Scale for Depression) for at least six months and having no axis I comorbidity. The inclusion criteria for FR were having no lifetime axis I diagnosis, and for HC no personal or family history for psychiatric disorders at the time of recruitment. The following exclusion criteria were applied to all groups: presence of auditory or visual impairment, history of neurosurgical intervention, being pregnant or breastfeeding, diagnosis of neurocognitive illness or substance use during the preceding six weeks before participating in the study. All participants were evaluated using the Structured Clinical Interview for Diagnostic Statistical Manual-IV (DSM-IV) (SCID-I). During the study period, forty-eight BDI patients, 35 unaffected FR, and 44 HC were assessed for inclusion. The following participants were excluded: 11 BDI patients were not euthymic at the time of the assessment; 7 BDI patients, 7 FR and 14 HC decided to withdraw from the study before MRI scanning; and 3 BDI patients, 4 FR and 1 HC were excluded for movement artifacts after MRI scanning. Thus, the final sample included 27 BDI patients, 24 FR (17 siblings, 6 offspring, 1 parent) and 29 HC.

2.2. MRI acquisition and preprocessing {#s0020}
--------------------------------------

MRI data was acquired using a 1.5 T Philips Tesla Achieva Magnetic Resonance Imaging Scanner and SENSE head coil/8 channel in the Department of Radiology, Dokuz Eylul University. 3D T1-fast field echo (FFE) axial images (repetition time (TR) =8.7 ms, echo time (TE) =4 ms, flip angle = 8 ^o^, field of view (FOV) =230 mm × 220 mm, slice thickness = 1 mm, number of signal averages (NSA) =1, matrix = 192) were used for surface-based analysis. In addition, axial T2 weighted turbo spin echo and proton density images (TR = 3000 ms, TE = 96 ms, flip angle = 90, FOV = 240 mm × 220 mm, slice thickness = 3 mm NSA = 1, Matrix = 256) were acquired for neuroradiological assessment.

CT and SA measures were obtained with the FreeSurfer version 5.3.0 image analysis software (<http://surfer.nmr.mgh.harvard.edu>/). The Freesurfer automated pipeline starts with motion and intensity correction and is followed by Talairach registration, normalization, skull stripping and subcortical segmentation. After subcortical segmentation, an initial surface by tilling the gray-white matter boundary (white matter surface) and a second surface by tracing the gray-CSF boundary (the pial surface) are generated. Following this, surfaces are inflated for visualization of the sulci and the topological defects are corrected with automatic topology fixing. The pipeline ends with surface registration to the spherical atlas, cortical parcellation and labelling. The distance between equivalent vertices of white matter surface and pial surface gives the CT and the sum of the area of the vertices on white matter surface gives the SA ([@bb0055]; [@bb0060]; [@bb0085]; [@bb0090]).

The Desikan-Killiany atlas was used for cortical parcellation and labelling which produces 34 regions per hemisphere. In terms of representations of the study ROIs in the Desikan-Killiany atlas; ACC is represented by a rostral and caudal region and the IFC is represented by three regions, the pars orbitalis, triangularis and opercularis.

Standardized quality protocol for the analysis of FreeSurfer mean CT and SA ROI data developed by the ENIGMA consortium was used for quality checking (QC) of the preprocessed images. This protocol uses R and Matlab scripts and Quality Assurance Tools for FreeSurfer and consists of three steps, namely, outlier detection, internal QC and external QC. Outlier detection creates a file which reveals the subjects that are outliers, and for which structures they are outliers for to make sure that these subjects inspected closely as QC proceed. In internal QC step, snapshots of preprocessed images from different brain sections are produced for each subject to visually inspect internal cortical segmentation for under/overestimations. In external QC, 4 images with external views of the segmentations from different angles are produced for visually checking cortical labels and anatomical boundaries and for confirming errors spotted on internal QC if there is any (<http://enigma.ini.usc.edu/protocols/imaging-protocols>). All preprocessed images in this study were subjected to these three steps and showed sufficient quality to be included in further analysis.

2.3. Statistical Analysis {#s0025}
-------------------------

All statistical analyses were carried out using Statistical Package for Social Science (SPSS Inc., v23). Comparisons of sociodemographic variables between groups were performed using chi-square test or analysis of variance.

For each subject, average CT and SA measures for each brain region were extracted to SPSS. To compare CT and SA measures among three groups (BDI/FR/HC), generalized estimating equations (GEE) models were used to accommodate within-subject dependencies arising from the inclusion of participants from the same family. GEE is a statistical analysis that extends the generalized linear models to allow for analysis of repeated measures or other correlated observations such as clustered data. It assumes that cases are dependent within subjects and independent between subjects and estimates a correlation matrix that represents the within subject dependencies as a part of the model ([@bb0155]). For each GEE model where CT was the dependent variable, we statistically controlled for age and gender and where SA was the dependent variable, we controlled for age, gender and total intracranial volume ([@bb0030]). The same analyses were repeated by restricting the FR group to siblings only (FR-SB) to constitute a more homogenous group in terms of genetic risk for BDI.

Where there was a significant difference of BDI group compared to HC on CT or SA measures, the effect of clinical variables, namely duration of illness, total number of episodes, episode frequency, current lithium, atypical antipsychotic and valproic acid use were also examined using univariate general linear models (UGLMs). For each UGLM where CT was the dependent variable, we statistically controlled for age and gender and where SA was the dependent variable, we controlled for age, gender and total intracranial volume ([@bb0030])

Corrections for multiple testing were carried out using bonferroni correction. ([@bb0195]). For ROI analysis, corrections were applied to the 10 tests (5 brain regions per each hemisphere) separately for CT and SA and the statistical significance level was set to *p* ≤ .005 (α/10). For exploratory analysis, corrections were applied to 58 tests (29 brain regions per each hemisphere) separately for CT and SA and the statistical significance level was set to *p* ≤ .0008 (α/58). For clinical variables, corrections were applied to 6 tests and the statistical significance level was set to *p* ≤ .008 (α/6). We presented the uncorrected *p* values throughout and only implied the findings as significant if the p values survived the Bonferroni correction as being equal or lower than the already set statistical significance level for each analysis mentioned above.

3. Results {#s0030}
==========

Demographic characteristics of the groups and the clinical variables for the BDI group are shown in [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}. There were no differences between groups in any of the demographic variables.Table 1Demographic characteristics of the groups.Table 1BD vs FR vs HCBD vs FR-SB vs HCBDI (n = 27)FR (n = 24)FR-SB (n = 17)HC (n = 29)Test-valuep-ValueTest-valuep-ValueAge in years (mean ± SD)36.3 ± 9.532.1 ± 10.934.7 ± 9.833.1 ± 9.0F = 1.310.28F = 0.830.44Gender: Female63% (n = 17)54% (*n* = 13)47.1% (*n* = 8)62% (*n* = 18)χ2 = 0.490.78χ2 = 1.290.52Education in years (mean ± SD)12.9 ± 2.811.5 ± 2.911.4 ± 2.913.6 ± 3.8F = 2.900.061F = 2.350.10Handedness: Right96% (*n* = 26)96% (*n* = 23)100% (n = 17)97% (*n* = 28)χ2 = 0.451χ2 = 0.791FR distribution71% siblings (n = 17)25% offspring (*n* = 6)4% parent (*n* = 1)[^2]Table 2Clinical characteristics of BDI group.Table 2Clinical variablesBDI (n = 27)Duration of illness in years (mean ± SD)10.25 ± 6.70Age of illness onset in years (mean ± SD)26.04 ± 8.18Total number of manic/hypomanic/mixed episodes (mean ± SD)2.96 ± 2.12Total number of depressive episodes (mean ± SD)1.78 ± 1.67Total number of episodes (mean ± SD)4.74 ± 2.99Episode frequency (mean ± SD)0.5 ± 0.2Current lithium use (%, n)66.7%, 18Current valproic acid use (%, n)40.7%, 11Current antipsychotic use (atypical),(%, n)59.3%, 16[^3]

3.1. ROI Analysis of ACC and IFC {#s0035}
--------------------------------

There were no significant group differences in CT of ACC and IFC between BDI, FR and HC ([Table 3](#t0015){ref-type="table"}). With regard to SA; the BDI group was significantly different from HC in the left pars triangularis (LPT) (B = 129.45, %95 CI = (50.12, 208.79), *p* = .001) ([Table 3](#t0015){ref-type="table"}).Table 3Comparison of CT and SA measurement of the ROIs between groups.Table 3BD vs FR vs HCBD vs FR-SB vs HCp-Valuesp-ValuesBrain RegionsBD (n = 27)FR (n = 24)FR-SB (n = 17)HC (n = 29)BD vs HCFR vs HCBD vs HCFR-SB vs HCCT (mm)L Caudal anterior cingulate2.52 ± 0.242.63 ± 0.242.68 ± 0.242.57 ± 0.220.6090.3090.6480.069L Rostral anterior cingulate2.77 ± 0.202.89 ± 0.212.90 ± 0.222.90 ± 0.290.0840.9240.0930.681L Pars opercularis2.51 ± 0.112.54 ± 0.142.53 ± 0.132.53 ± 0.170.8180.9760.8390.785L Pars orbitalis2.59 ± 0.212.59 ± 0.252.58 ± 0.262.58 ± 0.220.5550.9440.510.674L Pars triangularis2.38 ± 0.142.41 ± 0.922.41 ± 0.102.41 ± 0.170.9040.9390.9730.695R Caudal anterior cingulate2.45 ± 0.182.51 ± 0.292.46 ± 0.262.46 ± 0.220.8910.4040.9050.663R Rostral anterior cingulate2.67 ± 0.222.74 ± 0.192.75 ± 0.182.82 ± 0.200.0260.110.0280.365R Pars opercularis2.45 ± 0.142.49 ± 0.152.47 ± 0.142.54 ± 0.190.0950.2810.0850.302R Pars orbitalis2.60 ± 0.222.66 ± 0.232.62 ± 0.232.65 ± 0.250.7970.830.7950.832R Pars triangularis2.38 ± 0.172.42 ± 0.142.42 ± 0.142.45 ± 0.170.2310.4010.2520.799SA (mm^2^)L Caudal anterior cingulate664.74 ± 134.40626.25 ± 107.10630.00 ± 112.94644.20 ± 128.010.5760.4880.6250.577L Rostral anterior cingulate842.07 ± 122.58772.75 ± 115.92768.05 ± 99.26789.79 ± 132.290.0630.380.0690.381L Pars opercularis1548.03 ± 207.661613.75 ± 240.301618.05 ± 236.831506.86 ± 217.790.3160.1270.2330.072L Pars orbitalis616.51 ± 75.80626.29 ± 85.26622.58 ± 89.31602.75 ± 74.290.3070.4450.3360.501***L Pars triangularis**1266.63 ± 179.42**1184.75 ± 170.92**1209.11 ± 151.71**1148.03 ± 177.48**0.001***0.735***0.0003***0.267R Caudal anterior cingulate761.92 ± 155.54748.95 ± 143.68749.52 ± 153.06758.55 ± 158.540.8330.6070.8040.676R Rostral anterior cingulate677.92 ± 137.65625.50 ± 116.58610.29 ± 116.12659.96 ± 96.610.4950.1430.5060.078R Pars opercularis1331.14 ± 197.391303.41 ± 126.051301.58 ± 136.181284.37 ± 231.680.1950.960.1630.899R Pars orbitalis763.59 ± 101.67786.50 ± 64.85785.82 ± 68.28731.62 ± 110.320.1080.0650.1120.104R Pars triangularis1433.44 ± 266.491388.66 ± 206.831391.52 ± 219.391359.34 ± 251.240.1530.9410.1280.83[^4][^5]

Repeating the analysis with the FR-SB revealed similar results in terms of CT. Regarding SA, the same significant difference was established in the LPT in BDI group compared to HC (B = 133.09, %95 CI = (59.74, 206.43), *p* = .0003) ([Table 3](#t0015){ref-type="table"}).

3.2. Exploratory analysis of other brain regions {#s0040}
------------------------------------------------

BDI, FR and HC comparisons revealed no significant differences in CT or SA in the exploratory analysis (S1, S2). In terms of BDI, FR-SB and HC comparisons; there were no significant differences in CT measures of the other brain regions (S3). Regarding SA measures, FR-SB showed significant difference in SA of right STC compared to HC (B = 291.30, %95 CI = (141.01, 441.60) *p* = .0001) (S4).

3.3. Relationship between clinical variables and LPT SA {#s0045}
-------------------------------------------------------

There was no significant relationship between duration of illness (*p* = .15), total number of episodes (*p* = .97), episode frequency (*p* = .06), current lithium (*p* = .09), atypical antipsychotic (*p* = .44) or valproic acid use (p = .15) and SA of LPT in BDI group (S5).

4. Discussion {#s0050}
=============

In this study, we examined CT and SA abnormalities of ACC and IFC in patients with BDI, their FR/FR-SB and HC. We also carried out an exploratory analysis on other brain regions for SA and CT differences between groups. For our hypothesized regions, we showed larger SA of LPT in BDI group compared to HC. There were no significant relationships between SA of LPT and clinical variables in BDI patients. Our exploratory analysis revealed larger SA of STC in FR-SB compared to HC.

Pars triangularis (Broadmann Area (BA) 45) is one of the subparts of IFC that has a crucial role in semantic processing, memory and executive functions ([@bb0050]) which were shown to be impaired in BD patients with middle to large effect sizes ([@bb0040]). Most of the data considering IFC in BD including the ENIGMA data showed decreased volume or cortical thinning in this area of interest ([@bb0125]; [@bb0145]; [@bb0150]; [@bb0250]). On the other hand, there are also studies including our previous publication that revealed larger volumes in IFC in BD patients compared to HC ([@bb0120]; [@bb0240]). Regarding SA; there is only one study that revealed smaller SA of IFC in BD compared to HC ([@bb0010]).

Our finding of enlarged SA of LPT in BDI patients is in contrast with the previous studies and our primary hypothesis. One explanation for this finding could be the particular clinical characteristics of our sample. Previous studies showed that decreased volume in IFC in BD is associated with burden of illness, minimal lifetime exposure to lithium, being multi-episode rather than being first episode and increased incidence of manic episodes during clinical course ([@bb0005]; [@bb0120]; [@bb0190]). Our sample consisted of patients who were euthymic for a long period of time (approximately two years), had shorter periods of mood episodes throughout the illness course and were primarily on lithium at the time of the study or had used lithium previously. Considering these clinical characteristics of our patient sample, our finding of an enlarged SA in LPT may be arisen from the joint effects of better disease course and long-term lithium use. Nevertheless, in contrary to this interpretation, we couldn\'t show any association between SA of LPT and clinical variables in BDI group. One possible explanation for the negative findings in treatment variables could be the past exposure to these medications or the dose and duration of previous and current medication use of patients, which weren\'t taken into account in our study ([@bb0115]). In addition, for each medication group, comparisons were made between the patients who were taking the relevant medication with the ones who were not at the time of study entry. However, most of our patients were on different combinations of lithium, valproic acid and atypical antipsychotics and different medications might interact to produce effects that are different to those of each medication alone ([@bb0115]). On the other hand, our non-significant finding in total number of episodes and episode frequency may have arisen from not examining the manic and depressive episodes separately as they were shown to have different effects on gray matter ([@bb0005]; [@bb0185]).

From another aspect; SA measures are obtained from gray-white matter boundary and it is speculated that SA expansion might reflect not only the gray matter but also the pathology of underlying white matter fibers as more tension or shrinkage of these fibers could lead to deeper sulci and extended cortical SA ([@bb0075]). This speculation is supported with our diffusion tensor imaging findings in the same cohort, which revealed decreased fractional anisotropy in several white matter tracts including uncinate and inferior fronto-occipital fasciculus that are known to be closely related with IFC in BDI patients compared to controls ([@bb0245]).

When examining IFC SA of FR/FR-SB; our finding of no difference in any subparts of IFC compared to HC group is in line with numerous previous studies that measured gray matter volume, CT or SA in FR of BD patients ([@bb0130]; [@bb0205]; [@bb0220]; [@bb0235]). However, it should be noted that there are also studies that reported increased gray matter volume or decreased CT in IFC in FR of BD patients ([@bb0120]; [@bb0240]). As we found no differences in FR or FR-SB compared to HC, we represent our finding of increased SA of LPT in BDI as a disease marker rather than an endophenotype for BDI.

In contrast to our primary hypothesis, there were no significant differences in the CT or SA of ACC in BDI or FR/FR-SB compared to healthy controls. ACC (BA 24,25,32,33) is a highly connected region with limbic and prefrontal brain structures and it is involved in execution of behavior, shifting attention, emotion and memory functions of the brain ([@bb0050]). Although meta-analyses on volume and the majority of CT studies reported reduced gray matter measures ([@bb0045]; [@bb0125]; [@bb0150]) in ACC of BD patients compared to controls; our result is compatible with all studies examining SA ([@bb0070]; [@bb0100]; [@bb0135]; [@bb0160]; [@bb0230]) and a few studies of CT or volume, which failed to show any significant differences in this area of interest ([@bb0225]; [@bb0270]). One reason of our non-significant finding in BDI patients could be related to current or previous lithium use of the majority of our patient group as it has been associated with increased gray matter volumes in ACC ([@bb0115]). Another reason could be that we may have been underpowered to detect any gray matter change due to the relatively small sample size of this study. At the time of the analysis plan, a power calculation for ACC was performed using the results of a meta-analysis on gray matter volume changes in BD that revealed an effect size d of 1.17 for this area of interest ([@bb0170]) as there were only a few papers on CT and SA in BD with small sample sizes. After converting the effect size d = 1.17 of the ACC to f = 0.585, this power calculation (alpha = 0.05, power = 0.8) indicated a minimum total sample size of 32. On the other hand, a mega-analysis on CT and SA in BD ([@bb0145]) compared to HC was published after the data collection and analysis were completed for this study. This mega-analysis enabled us to perform a second power calculation using an effect size for CT and SA of ACC (rather than volume) in BD which was the scope of this study. The largest effect size d that the mega-analysis reported for CT and SA measures of ACC subparts was used for the second power calculation, which was 0.153 for the CT of left rostral ACC in BD. After converting effect size d of 0.153 to f as 0.0765, this power calculation (alpha = 0.05, power = 0.8) revealed that the minimum total sample size needed is 1650. To conclude, although our sample size was appropriately powered to show differences in gray matter volume measures, it was clearly underpowered to detect any differences in CT and SA between groups.

In terms of FR of BD; our study is in line with the majority of the studies on volume, CT or SA, which failed to show any significant differences in ACC in relatives of BD compared to HC ([@bb0130]; [@bb0205]; [@bb0220]; [@bb0235]; [@bb0255]). Overall, despite our non-significant result in this area, ACC seems to be a marker related with disease but not a candidate to be an endophenotype. We propose that ACC should continue to be a region of interest for BD and be studied in larger drug-free patient groups.

Our exploratory analysis revealed larger SA in FR-SB compared to HC. STC is known for its role in processing auditory stimuli, language, speech and communicative gestures ([@bb0050]). Looking at the literature regarding STC in BD patients, most of the volume and CT studies showed gray matter decrease in this area of interest ([@bb0125]; [@bb0180]; [@bb0260]). On the other hand, there are also studies that reported increased volume and SA in BD compared to HC ([@bb0015]; [@bb0100]). In regard to FR of BD, the majority of the studies on volume, CT or SA were not able to find any differences in STC compared to HC ([@bb0130]; [@bb0205]; [@bb0220]; [@bb0235]; [@bb0255]). Taken together the current literature and our non-significant finding between BDI and HC, our finding of the enlargement of STC in FR-SB may be a resilience factor and needs to be further investigated in the future studies.

Comparing the results of this study with our volumetric analysis of the same cohort, the only overlap was the enlargement of LPT in BDI patients compared to controls. A comprehensive comparison of measuring gray matter with different analysis techniques is beyond the scope of this study but possible reasons will be briefly discussed. First of all, CT, SA and volume measures follow different neurodevelopmental trajectories both in pattern and timing and should be evaluated independently ([@bb0215]). Second, volumetric measures may be partially mediated by cortical measures and this discrepancy may have derived from local gyrification index, a third surface measure which contributes to gray matter volume and was not measured in this study ([@bb0210]). Apart of that, this difference may be related with minor gray matter changes in CT and SA that can\'t be detected with current analysis techniques but becoming apparent as a cumulative manner in volume measures. From another point of view, this discrepancy could be the result of different statistical procedures undertaken in each study. In our volume analysis, the group effect was controlled for total intracranial volume and years of education, and the multiple comparison correction was carried out with Monte-Carlo Stimulation. In this study, we controlled group effect with different variables including age, gender, total intracranial volume and Bonferroni corrections were carried throughout. Furthermore, different softwares were used as Statistical Parametric Mapping for volume and FreeSurfer for CT and SA analysis. This could be the other reason for the different results as these softwares follow different techniques in segmentation and spatial normalization ([@bb0165]).

Our study has several limitations. First, small sample sizes in each group could have increased the possibility of type II error and it makes our results difficult to generalize to the wider patient population. Second, our results of FR group should be evaluated with the information that siblings, parents and offspring have different genetic risk for BD. Furthermore, it has been shown that approximately the 45% of bipolar disorder patients have their illness onset before the mean age of 21 and up to 80% before the mean age of 35 ([@bb0105]).The mean age of our FR group was 32 and FR-SB was 34, which were very near to exceed the defined age threshold for the onset of illness. From this aspect, our relative sample could be at low risk or resilient for developing BDI which may have hindered finding any potential brain areas as a risk marker.

In conclusion, our result of increased SA in LPT of BDI compared to HC could be a disease marker and increased SA in STC of FR-SB compared to HC could be a marker related with resilience. Longitudinal studies are needed in BD patients and high-risk groups to clarify the discrepancies between cross-sectional studies and more studies should be conducted on the morphometric characteristics of cortical SA.
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==============================

Supplementary materialImage 1

Acknowledgement {#s0055}
===============

This report represents independent research funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.

Funding {#s0060}
=======

This work was supported by Dokuz Eylul University Department of Scientific Research Projects Funding (Project no: 2012.KB.SAG.062). Matthew J. Kempton is funded by an MRC Career Development Fellowship (grant number MR/J008915/1).

Declaration of interest {#s0065}
=======================

Nefize Yalin has been an investigator in clinical studies conducted together with Janssen-Cilag, Corcept Therapeutics and COMPASS Pathways. Aysegul Ozerdem has received honoraria from Servier, Pfizer, GSK, BMS and Sanofi during last five years. The rest of the authors declare no conflict of interest.

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.nicl.2019.101695>.

[^1]: Both authors contributed equally to this work.

[^2]: BDI: bipolar disorder type I, FR: first degree relatives, FR-SB: siblings, HC: healthy controls.

[^3]: BDI: bipolar disorder type I.

[^4]: BDI: bipolar disorder type I, FR: first degree relatives, FR-SB: siblings; HC: healthy controls, CT: cortical thickness, SA: surface area, ROI: region of interest.

[^5]: Statistically significant results that were survived Bonferroni correction for multiple comparisons (p ≤ 0.005) are highlighted in bold and italics.
